Johnson & Johnson (NYSE:JNJ) Shares Bought by Security National Bank of SO Dak

Security National Bank of SO Dak grew its holdings in Johnson & Johnson (NYSE:JNJ) by 1.5% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 15,349 shares of the company’s stock after buying an additional 225 shares during the quarter. Johnson & Johnson comprises approximately 2.5% of Security National Bank of SO Dak’s portfolio, making the stock its 8th largest holding. Security National Bank of SO Dak’s holdings in Johnson & Johnson were worth $2,138,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Virtus ETF Advisers LLC acquired a new stake in Johnson & Johnson in the second quarter worth about $25,000. Krane Funds Advisors LLC acquired a new stake in Johnson & Johnson in the second quarter worth about $26,000. Crewe Advisors LLC increased its position in Johnson & Johnson by 725.9% in the second quarter. Crewe Advisors LLC now owns 223 shares of the company’s stock worth $31,000 after purchasing an additional 196 shares during the period. Permanens Capital L.P. increased its position in Johnson & Johnson by 50.0% in the second quarter. Permanens Capital L.P. now owns 300 shares of the company’s stock worth $42,000 after purchasing an additional 100 shares during the period. Finally, Thor Advisors LLC acquired a new stake in Johnson & Johnson in the first quarter worth about $69,000. Institutional investors own 72.01% of the company’s stock.

Shares of NYSE:JNJ traded up $1.28 during trading on Friday, hitting $131.39. 5,855,789 shares of the company’s stock traded hands, compared to its average volume of 7,392,434. Johnson & Johnson has a 52 week low of $121.00 and a 52 week high of $148.99. The company has a current ratio of 1.33, a quick ratio of 1.04 and a debt-to-equity ratio of 0.46. The company has a market cap of $342.22 billion, a price-to-earnings ratio of 16.06, a price-to-earnings-growth ratio of 2.19 and a beta of 0.68. The company has a 50-day moving average price of $130.02 and a 200-day moving average price of $135.75.



Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, July 16th. The company reported $2.58 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.42 by $0.16. Johnson & Johnson had a return on equity of 38.63% and a net margin of 20.08%. The business had revenue of $20.56 billion for the quarter, compared to analysts’ expectations of $20.39 billion. During the same quarter in the previous year, the business posted $2.10 EPS. Johnson & Johnson’s revenue for the quarter was down 1.3% on a year-over-year basis. On average, analysts predict that Johnson & Johnson will post 8.6 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th were issued a dividend of $0.95 per share. This represents a $3.80 annualized dividend and a dividend yield of 2.89%. The ex-dividend date was Monday, August 26th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 46.45%.

JNJ has been the subject of a number of research reports. Royal Bank of Canada reiterated a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, July 16th. Barclays initiated coverage on Johnson & Johnson in a report on Friday, June 21st. They set a “hold” rating and a $140.00 target price on the stock. Credit Suisse Group set a $156.00 target price on Johnson & Johnson and gave the stock a “buy” rating in a report on Tuesday, August 27th. Zacks Investment Research cut Johnson & Johnson from a “buy” rating to a “hold” rating and set a $139.00 target price on the stock. in a report on Thursday, July 18th. Finally, Bank of America restated a “hold” rating and set a $150.00 target price on shares of Johnson & Johnson in a report on Tuesday, July 16th. Five investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $150.60.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Story: Market Capitalization

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.